- Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics
- Cybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trials
- Ketamine is a dissociative injected anesthetic that blocks sensory perception
Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the Kernel Flow technology; the study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/BW1Jn).
“We still have much to learn about what is occurring in the brain during a psychedelic experience,” said Cybin CEO Doug Drysdale. “This first-of-its-kind, Cybin-sponsored study using the Kernel Flow device aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel.”
Cybin announced a partnership with Kernel earlier this year. The two companies are working together to leverage Kernel’s proprietary Kernel Flow device for psychedelic-based studies and clinical trials. The Kernel Flow device is the first commercially scalable time-domain near-infrared spectroscopy (TD-fNIRS) system in history. The device uses quantitative neuroimaging technology that measures brain activity in real time when users wear the device during psychedelic treatments.
According to Cybin, Kernel Flow uses pulsed light to increase measured brain information. In contrast with electroencephalography (“EEG”) electrodes, which typically require gel on the head, or functional magnetic resonance imaging (“fMRI”) studies, which require a participant to lie in a scanner, the Flow device is a wearable helmet. The device has potential for broad use in neuroscientific or physiological studies of brain activity during psychedelic use; little direct neuroimaging research of psychedelic effects, in vivo, have been attempted until now, and that research has never been done with a wearable device.
The study will use the device to study ketamine, a dissociative injected anesthetic that blocks sensory perception and has been available by prescription in the United States since the 1970s for human and veterinary uses (https://ibn.fm/uv5Zk). A form of ketamine has been approved for treatment-resistant depression and is approved for use in depressed patients with acute suicidal ideation or behavior. In the United States, ketamine is a class III scheduled drug and is approved for use in hospitals and other medical settings as an anesthetic.
“Psychedelics have shown great promise for mental health and wellness, and Kernel’s collaboration with Cybin has the promise of offering increased scientific rigor for their development,” said Kernel founder and CEO Bryan Johnson.
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.